WHO adds two candidate vaccines to Bundibugyo Ebola trial
The WHO adds ChAdOx1 and mRNA-1469 to the Tumaini trial in Congo, the first aimed at the Bundibugyo strain of Ebola. First results expected in early 2027.
The World Health Organization (WHO) recommended on November 4, 2026, adding two candidate vaccines, ChAdOx1 and mRNA-1469, to the Tumaini trial in the Democratic Republic of the Congo. It is the first time that vaccines designed specifically against the Bundibugyo ebolavirus, a strain with no authorized immunization, are being evaluated during an outbreak.
The ongoing outbreak has accumulated 10,532 confirmed cases and 5,126 deaths as of November 1, 2026, and now reaches eight Congolese provinces, according to ONU Noticias. The only vaccine prequalified by the WHO, Ervebo, protects against the Zaire virus and has no specific authorization for Bundibugyo, so patient management is based on symptoms, according to Saludiario. Outside Congo, La Nación reports nine cases in Kenya with two deaths, one in Nigeria and twenty in Uganda. The question this case leaves for Latin America is one of infrastructure: surveillance, diagnosis and cold chain, the services a deployment of this kind requires.
The Tumaini trial began on October 23 in Bunia, the capital of Ituri, and is led by the DRC's National Institute of Biomedical Research with the University of Antwerp, Epicentre, Doctors Without Borders, the Antwerp Institute of Tropical Medicine and the Africa Centres for Disease Control and Prevention, with funding from CEPI, according to the WHO statement. An independent technical group reviewed preclinical and early clinical data; each vaccine enters when the country authorizes it. The protocol uses ring vaccination, which immunizes contacts of confirmed cases and of deceased people; there are already four rings and others in preparation. ChAdOx1, from Oxford with the Serum Institute of India, uses a chimpanzee adenovirus vector. mRNA-1469, from Moderna, uses messenger RNA in lipid nanoparticles. The first results of the vaccine trial are expected in early 2027.
The timeline leaves two operational questions: what manufacturing capacity, regulatory registration and cold chain exist in the region when the product is authorized, and how ring vaccination integrates with surveillance systems on a limited budget. For suppliers of inputs and laboratory services, the trial sets the deadline: results in early 2027.
This article was written with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.
Sources
- Un ensayo incorporará dos nuevas vacunas experimentales contra el ébola, mientras continúa la investigación sobre tratamientos
- Ebola en RDC: deux nouveaux vaccins à l'essai face à une épidémie meurtrière
- OMS propone 2 nuevas vacunas contra el ébola cepa Bundibugyo
- Vacunas en carrera contra el ébola: la OMS amplía los ensayos en medio de un brote que ya dejó más de 5300 muertos